Hunter N, Nakayama T, Ito H, Woo S, Milas L
Department of Experimental Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Clin Exp Metastasis. 1992 Nov;10(6):431-6. doi: 10.1007/BF00133472.
Experiments were designed to investigate the therapeutic efficacy of interleukin-2 (IL-2) combined with radiotherapy. The effect of IL-2 and local thoracic irradiation (LTI) was determined on 4-day-old lung micrometastases, generated by i.v. injection of tumor cells into mice. IL-2 alone reduced the number of lung nodules more effectively when given from 1 to 4 than 4 to 7 days after tumor cell injection. The combination of IL-2 and LTI reduced the number of lung nodules more than did the individual treatments alone. When IL-2 therapy was combined with local irradiation of 8-mm leg tumors, there was no change in the TCD50 (radiation dose yielding 50% local tumor control). However, the combination of IL-2 treatment on days 1-4 with irradiation of tumor-bearing legs on day 1 after inoculation of tumor cells reduced the TCD50 by a factor of 1.3. These results show that IL-2 improves tumor radiotherapy, but that the improvement depends on anatomic localization and tumor size at the time of treatment.
实验旨在研究白细胞介素 -2（IL -2）联合放疗的治疗效果。通过静脉注射肿瘤细胞给小鼠，来确定IL -2和局部胸部照射（LTI）对4日龄肺微转移灶的影响。单独使用IL -2时，在肿瘤细胞注射后1至4天给药比4至7天给药更有效地减少了肺结节数量。IL -2与LTI联合使用比单独的个体治疗减少了更多的肺结节数量。当IL -2治疗与8毫米腿部肿瘤的局部照射联合时，TCD50（产生50%局部肿瘤控制的辐射剂量）没有变化。然而，在接种肿瘤细胞后第1天，将第1至4天的IL -2治疗与荷瘤腿部照射相结合，使TCD50降低了1.3倍。这些结果表明，IL -2可改善肿瘤放疗效果，但改善程度取决于治疗时的解剖定位和肿瘤大小。
